Platelets and vascular risk: An option for treatment

Current Pharmaceutical Design

Volumn 13, Issue 16, 2007, Pages 1669-1683

  Jagroop, I A ^a   Kakafika, A I ^a   Mikhailidis, D P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Aggregation; Aspirin; Clopidogrel; Myocardial infarction; Platelet; Stroke; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; LOTRAFIBAN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NADROPARIN; ORBOFIBAN; PHOSPHODIESTERASE III INHIBITOR; PICOTAMIDE; PLACEBO; SIBRAFIBAN; STREPTOKINASE; SULFINPYRAZONE; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; VASODILATOR AGENT; WARFARIN; XEMILOFIBAN; XIMELAGATRAN;

ABDOMINAL PAIN; ARTERY DISEASE; BLEEDING; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CORONARY ARTERY DISEASE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; EPIDEMIOLOGICAL DATA; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; NEUTROPENIA; NEUTROPHIL; OPTIMAL DRUG DOSE; PERIPHERAL EDEMA; PRIMARY PREVENTION; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; RHINITIS; SECONDARY PREVENTION; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; ULCER; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

EID: 34250850787     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780831383     Document Type: Review

References (219)

1. Kaluzhny Y, Ravid K. Role of apoptotic processes in platelet biogenesis. Acta Haematol 2004; 111: 67-77.
2. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-7.
3. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-54.
4. Massberg S, Schulz C, Gawaz M. Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med 2003; 3: 147-62.
5. Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988; 18: 399-404.
6. Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001; 22: 451-8.
7. Mehta JL, Nicolini FA, Donnelly WH, Nichols WW. Platelet-leukocyte-endothelial interactions in coronary artery disease. Am J Cardiol 1992; 69: 8B-13B.
8. Luscher TF. Thrombocyte-vascular wall interaction and coronary heart disease. Schweiz Med Wochenschr 1991; 121: 1913-22.
9. de Gaetano G, Cerletti C, Nanni-Costa MP, Poggi A. The blood platelet as an inflammatory cell. Eur Respir J Suppl 1989; 6: 441s-5s.
10. Mehta JL, Nichols WW, Mehta P. Neutrophils as potential participants in acute myocardial ischemia: Relevance to reperfusion. J Am Coll Cardiol 1988; 11:1309-16.
11. Baumgartner HR, Hosang M. Platelets, platelet-derived growth factor and arteriosclerosis. Experientia 1988; 44: 109-12.
12. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: Is there a practical index of platelet activity? Clin Appl Thromb Hemost 2003; 9: 177-90.
13. Chen YC, Wu KK. A comparison of methods for the study of platelet hyperfunction in thromboembolic disorders. Br J Haematol 1980; 46: 263-8.
14. Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999; 6: 342-8.
15. Bick RL. Laboratory evaluation of platelet dysfunction. Clin Lab Med 1995; 15: 1-38.
16. Jagroop IA, Mikhailidis DP. Effect of endothelin-1 on human platelet shape change: Reversal of activation by naftidrofuryl. Platelets 2000; 11: 272-7.
17. Jagroop IA, Clatworthy I, Lewin J, Mikhailidis DP. Shape change in human platelets: Measurement with a channelyzer and visualisation by electron microscopy. Platelets 2000; 11: 28-32.
18. Jagroop IA, Mikhailidis DP. Mean platelet volume is a useful parameter: a reproducible routine method using a modified Coulter Thrombocytometer. Platelets 2001; 12: 171.
19. Jagroop IA, Mikhailidis DP. Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Hum Hypertens 2001; 15: 203-7.
20. Jagroop IA, Mikhailidis DP. An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets 2000; 11: 161-5.
21. Jagroop IA, Burnstock G, Mikhailidis DP. Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets. Platelets 2003; 14: 15-20.
22. Bancroft AJ, Abel EW, Mclaren M, Belch JJ. Mean platelet volume is a useful parameter: A reproducible routine method using a modified Coulter thrombocytometer. Platelets 2000; 11: 379-87.
23. Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399-404.
24. Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: Methodological issues. Platelets 2002; 13: 301-6
25. Michelson AD, Barnard MR, Krueger LA, Frelinger AL, III, Furman MI. Evaluation of platelet function by flow cytometry. Methods 2000; 21: 259-70.
26. Vidal C, Spaulding C, Picard F, Schaison F, Melle J, Weber S, et al. Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. Thromb Haemost 2001; 86: 784-90.
27. Matzdorff A. Platelet function tests and flow cytometry to monitor antiplatelet therapy. Semin Thromb Hemost 2005; 31: 393-9.
28. Merten M, Thiagarajan P. P-selectin in arterial thrombosis. Z Kardiol 2004; 93: 855-63.
29. Kappelmayer J, Nagy B, Jr., Miszti-Blasius K, Hevessy Z, Setiadi H. The emerging value of P-selectin as a disease marker. Clin Chem Lab Med 2004; 42: 475-86.
30. Amin HM, Ahmad S, Walenga JM, Hoppensteadt DA, Leitz H, Fareed J. Soluble P-selectin in human plasma: Effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Clin Appl Thromb Hemost 2000; 6: 71-6.
31. Blann AD, Lip GY, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: A comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77: 1077-80.
32. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-5.
33. Atalar E, Haznedaroglu Y, Aytemir K, Ozer N, Aksoyek S, Ovunc K, et al. Circulating adhesion molecules in patients with stable coronary artery disease. Int J Hematol 2000; 72: 507-11.
34. Barradas MA, Jagroop IA, Mikhailidis DP. Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets. Clin Chim Acta 1994; 230: 157-67.
35. Kaplan KL, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202.
36. Matzdorff AC, Kuhnel G, Kemkes-Matthes B, Voss R. Comparison of GP IIB/ IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer. J Thromb Thrombolysis 2001; 12: 129-39.
37. Madan M, Berkowitz SD, Christie DJ, Jennings LK, Smit AC, Sigmon KN, et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 2001; 141: 226-33.
38. Peters AJ, Borries M, Gradaus F, Jax TW, Schoebel FC, Strauer BE. In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease. J Thromb Thrombolysis 2001; 12: 263-72.
39. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 2002; 13: 493-7.
40. Fontana P, Reny JL. Pharmacogenetics and antiplatelet drugs. Rev Med Interne 2005; 26: 725-32.
41. Maree AO, Fitzgerald DJ. Aspirin and coronary artery disease. Thromb Haemost 2004; 92: 1175-81.
42. Nakayama T. Prostacyclin synthase gene: Genetic polymorphisms and prevention of some cardiovascular diseases. Curr Med Chem Cardiovasc Hematol Agents 2005; 3: 157-64.
43. Rozalski M, Boncler M, Luzak B, Watala C. Genetic factors underlying differential blood platelet sensitivity to inhibitors. Pharmacol Rep 2005; 57: 1-13.
44. Yee DL, Bray PF. Clinical and functional consequences of platelet membrane glycoprotein polymorphisms. Semin Thromb Hemost 2004; 30: 591-600.
45. Zhao YH, Wang YN, Zhu JQ, Ma AQ, Cui CZ, Zhao QB. Association of the polymorphism of platelet membrane glycoprotein I a gene with myocardial infarction. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003; 20: 417-20.
46. Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 2002; 14: 51-8.
47. Howard PA. Aspirin resistance. Ann Pharmacother 2002; 36: 1620-4.
48. Jefferson BK, Foster JH, McCarthy JJ, Ginsburg G, Parker A, Kottke-Marchant K, et al. Aspirin resistance and a single gene. Am J Cardiol 2005; 95: 805-8.
49. Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003; 42: 1115-9.
50. Martin CP, Talbert RL. Aspirin resistance: An evaluation of current evidence and measurement methods. Pharmacotherapy 2005; 25: 942-53.
51. Papadakis JA, Ganotakis ES, Mikhailidis DP. Beneficial effect of moderate alcohol consumption on vascular disease: Myth or reality? J R Soc Health 2000; 120: 11-5.
52. Mikhailidis DP, Barradas MA, Epemolu O, Dandona P. Ethanol ingestion inhibits human whole blood platelet impedance aggregation. Am J Clin Pathol 1987; 88: 342-5.
53. Jeremy JY, Mikhailidis DP, Pittilo RM. Cigarette smoking and cardiovascular disease. J Roy Soc Health 1995; 115: 289-95.
54. Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. The effects of antihypertensive therapy on haemostatic parameters. Curr Pharm Des 2003; 9: 2445-64.
55. Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des 2003; 9: 2425-43.
56. Munger MA, Hawkins DW. Atherothrombosis: Epidemiology, pathophysiology, and prevention. J Am Pharm Assoc (Wash.DC.) 2004; 44: S5-12.
57. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001; 88: 787-800.
58. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005; 142: 251-9.
59. Denardo SJ, Davis KE, Tcheng JE. Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. Am Heart J 2005; 149: 138-44.
60. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004; 148: 263-8.
61. Hankey GJ, Eikelboom JW. Antiplatelet drugs. Med J Aust 2003; 178: 568-74.
62. Hankey GJ. Current oral antiplatelet agents to prevent atherothrombosis. Cerebrovasc Dis 2001; 11(Suppl 2): 11-7.
63. Patrono C. Aspirin: New cardiovascular uses for an old drug. Am J Med 2001; 110: 62S-5S.
64. Montalescot G. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease. Clin Cardiol 2000; 23(Suppl 6): VI-22.
65. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2000; CD001246.
66. Mousa SA. Antiplatelet therapies: From aspirin to GPIIb/IIIa-receptor antagonists and beyond. Drug Discov Today 1999; 4: 552-61.
67. Schror K. Anti-integrins - new platelet function inhibitors for therapy and prevention of acute coronary syndrome. Wien Klin Wochenschr 1999; 111: 90-7.
68. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
69. Elwood PC, Renaud S, Beswick AD, O'Brien JR, Sweetnam PM. Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort. Heart 1998; 80: 578-82.
70. Elwood PC, Beswick AD, Sharp DS, Yarnell JW, Rogers S, Renaud S. Whole blood impedance platelet aggregometry and ischemic heart disease. The Caerphilly Collaborative Heart Disease Study. Arteriosclerosis 1990; 10: 1032-6.
71. Elwood PC, Renaud S, Sharp DS, Beswick AD, O'Brien JR, Yarnell JW. Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. Circulation 1991; 83: 38-44.
72. Elwood PC, Beswick A, Pickering J, McCarron P, O'Brien JR, Renaud SR, et al. Platelet tests in the prediction of myocardial infarction and ischaemic stroke: Evidence from the Caerphilly Prospective Study. Br J Haematol 2001; 113: 514-20.
73. Sharp DS, Beswick AD, O'Brien JR, Renaud S, Yarnell JW, Elwood PC. The association of platelet and red cell count with platelet impedance changes in whole blood and light-scattering changes in platelet rich plasma: Evidence from the Caerphilly Collaborative Heart Disease Study. Thromb Haemost 1990; 64: 211-5.
74. Sharp DS, Ben Shlomo Y, Beswick AD, Andrew ME, Elwood PC. Platelet aggregation in whole blood is a paradoxical predictor of ischaemic stroke: Caerphilly Prospective Study revisited. Platelets 2005; 16: 320-8.
75. Yip HK, Chen SS, Liu JS, Chang HW, Kao YF, Lan MY, et al. Serial changes in platelet activation in patients after ischemic stroke: Role of pharmacodynamic modulation. Stroke 2004; 35: 1683-7.
76. Holme S, Sixma JJ, Wester J, Holmsen H. ADP-induced refractory state of platelets in vitro. II. Functional and ultra studies on gel filtered platelets. Scand J Haematol 1977; 18: 267-78.
77. Barradas MA, O'Donoghue S, Jagroop IA, Mikhailidis DP. Laboratory techniques in drug development 2: Advantages of whole blood platelet aggregation measured be a cell counter Coulter T-890 in drug evaluation. J Drug Dev 1992; 5: 155-66.
78. Mathur A, Robinson MS, Cotton J, Martin JF, Erusalimsky JD. Platelet reactivity in acute coronary syndromes: Evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb Haemost 2001; 85: 989-4.
79. Breddin HK, Lippold R, Bittner M, Kirchmaier CM, Krzywanek HJ, Michaelis J. Spontaneous platelet aggregation as a predictive risk factor for vascular occlusions in healthy volunteers? Results of the HAPARG Study. Haemostatic parameters as risk factors in healthy volunteers. Atherosclerosis 1999; 144: 211-9.
80. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
81. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: 527-32.
82. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30: 1288-95.
83. Herbert JM, Frehel D, Vallée E, Kieffer G, Gouy D, Necciari J, et al. A novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 93 AD; 11: 180-98.
84. Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert JM. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001; 283: 379-83.
85. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2281-5.
86. Leon C, Vial C, Gachet C, Ohlmann P, Hechler B, Cazenave JP, et al. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb Haemost 1999; 81: 775-81.
87. Weber AA, Reimann S, Schror K. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol 1999; 126: 415-20.
88. Schror K. Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vasc Med 1998; 3: 247-51.
89. Weber AA, Schror K. Pharmacology of ticlopidine and clopidogrel in comparison with acetylsalicylic acid. Internist (Berl) 1997; 38: 1115-20.
90. Longstreth KL, Wertz JR. High-dose clopidogrel loading in percutaneous coronary intervention. Ann Pharmacother 2005; 39: 918-22.
91. Seyfarth HJ, Koksch M, Roethig G, Rother T, Neugebauer A, Klein N, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J 2002; 143: 118-23.
92. Gawaz M, Seyfarth M, Muller I, Rudiger S, Pogatsa-Murray G, Wolf B, et al. Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. Am J Cardiol 2001; 87: 332-6, A9.
93. Muller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schomig A, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-3.
94. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-72.
95. Pache J, Kastrati A, Mehilli J, Gawaz M, Neumann FJ, Seyfarth M, et al. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. Catheter Cardiovasc Interv 2002; 55: 436-41.
96. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099-106.
97. Matsagas M, Jagroop IA, Geroulakos G, Mikhailidis DP. The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease. Clin Appl Thromb Hemost 2003; 9: 115-20.
98. Dauterman K, Topol E. Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction. Ann Med 2002; 34: 514-22.
99. Chen AA, Sabatine MS. The management of unstable angina and non-ST-segment elevation myocardial infartion. Minerva Cardioangiol 2003; 51: 433-45.
100. Casella G, Ottani F, Pavesi PC, Sangiorgio P, Rubboli A, Galvani M, et al. Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: An updated meta-analysis. Ital Heart J 2003; 4: 677-84.
101. Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: The CADET trial. J Thromb Haemost 2004; 2: 1934-40.
102. Eikelboom JW, Hankey GJ, Thomas J, Claxton A, Yi Q, Gilmores G, et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are ieast inhibited by aspirin:a randomized crossover trial. J Thromb Haemost 2005; 3: 2649-55.
103. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
104. Visseren FL, Eikelboom BC. Oral anticoagulant therapy in patients with peripheral artery disease. Semin Vasc Med 2003; 3: 339-44.
105. Comerota AJ. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. Atheroscler Suppl 2005; 6: 13-9.
106. Diehm C, Lawall H, Huber R. Antiplatelet therapy in patients with peripheral arterial disease (PAD). Med.Klin (Munich) 2004; 99(Suppl 1): 14-20.
107. Matsagas MI, Geroulakos G, Mikhailidis DP. The role of platelets in peripheral arterial disease: Therapeutic implications. Ann Vasc Surg 2002; 16: 246-58.
108. Aronow WS. Management of peripheral arterial disease. Cardiol Rev 2005; 13: 61-8.
109. Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 2004; 15: 117-25
110. Pasqualini L, Pirro M, Lombardini R, Ciuffetti G, Dragani P, Mannarino E. A human model of platelet-leucocyte adhesive interactions during controlled ischaemia in patients with peripheral vascular disease. J Clin Pathol 2002; 55: 946-50.
111. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94.
112. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-32.
113. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073-6.
114. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2: 637-43.
115. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004; 25: 166-81.
116. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitz-Gerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-7.
117. Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137-41.
118. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206-11.
119. Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997; 96: 1109-16.
120. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30.
121. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340: 1421-5.
122. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet 1991; 338: 1345-9.
123. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996,143:1-13.
124. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med 1991; 325: 1261-6.
125. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353: 2179-84.
126. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiatry 1991; 54:1044-54.
127. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-30.
128. Liberopoulos EN, Elisaf MS, Tselepis AD, Archimandritis A, Kiskinis D, Cokkinos D, et al. Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: Where we are now? Platelets 2006; 17: 1-6.
129. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682-7.
130. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95: 1218-22.
131. Fork FT, Lafolie P, Toth E, Lindgarde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol 2000; 35: 464-9.
132. Iso H, Hennekens CH, Stampfer MJ, Rexrode KM, Colditz GA, Speizer FE, et al. Prospective study of aspirin use and risk of stroke in women. Stroke 1999; 30: 1764-71.
133. Mene P, Pugliese F, Patrono C. The effects of nonsteroidal antiinflammatory drugs on human hypertensive vascular disease. Semin Nephrol 1995; 15: 244-52.
134. Wong S, Appleberg M, Ward CM, Lewis DR. Aspirin resistance in cardiovascular disease: A review. Eur J Vasc Endovasc Surg 2004; 27:456-65.
135. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
136. De Schryver EL AAvGJ. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2004; CD001820.
137. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-71.
138. Pulcinelli FM, Riondino S, Celestini A, Pignatelli P, Trifiro E, Di Renzo L, et al. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 2005; 3: 2784.
139. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-7.
140. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 129-35.
141. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 233-41.
142. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Lancet 2001; 89-95.
143. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
144. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313-6.
145. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006-10.
146. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
147. Felmeden DC, Lip GY. Antithrombotic therapy in hypertension: A Cochrane Systematic review. J Hum Hypertens 2005; 19:185-96.
148. Preventive Services Task Force.Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med 2002,157-60.
149. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-91.
150. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004; S72-S3.
151. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349-60.
152. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11.
153. Wallentin LC. Aspirin (75 mg/d) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991; 18: 1587-93.
154. Smith SC, Jr., Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001; 37: 2215-39.
155. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. N Engl J Med 1978; 299: 53-9.
156. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
157. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCICURE study. Lancet 2001; 358: 527-33.
158. Steinhubl SR, Berger PB, Mann JT, III, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 288: 2411-20.
159. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
160. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005; 366: 1607-21.
161. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-7.
162. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005; 111: 2233-40.
163. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2005; 150: 401.
164. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004,148:263-8.
165. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292: 1867-74.
166. FitzGerald GA. Dipyridamole. N Engl J Med 1987; 316: 1247-57.
167. Sudlow C. What is the role of dipyridamole in long-term secondary prevention after an ischemic stroke or transient ischemic attack? CMAJ 2005; 173: 1024-6.
168. De Schryver EL. Dipyridamole in stroke prevention: Effect of dipyridamole on blood pressure. Stroke 2003; 34: 2339-42.
169. Muller TH, Su CA, Weisenberger H, Brickl R, Nehmiz G, Eisert WG. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 1990; 30: 179-86.
170. Leonardi-Bee J, Bath PM, Bousser MG, Davalos A, Diener HC, Guiraud-Chaumeil B, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: A meta-analysis of individual patient data from randomized controlled trials. Stroke 2005; 36: 162-8.
171. Bedetti G, Pizzi C, Gabrieli L, Varga A, Pasanisi E, Bugiardini R, et al. The beneficial effect of insulin, glucose, and dipyridamole on regional left ventricular function early after acute myocardial infarction. Int J Cardiol 2005; 102: 255-8.
172. Cadroy Y, Thalamas C, Sakariassen K, Boneu B. Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers. Thromb Res 2005; 116: 293-300
173. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-72.
174. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
175. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-20.
176. Hass WK, Easton JD, Adams HP, Jr., Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501-7.
177. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial. JAMA 2003; 289: 2947-57.
178. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 301-8.
179. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-9.
180. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 2001; 119: 39S-63S.
181. Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B. Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease. Herz 2003; 28: 393-403.
182. Mak KH, Moliterno DJ. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Curr Cardiol Rep 1999; 1: 199-205.
183. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-61.
184. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349: 1422-8.
185. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96: 1445-53.
186. Cox D. Oral GPIIb/IIIa antagonists: What went wrong? Curr. Pharm Des 2004; 10: 1587-96.
187. Newby LK, Califf RM, White HD, Harrington RA, Van de WF, Granger CB, et al. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med 2002; 112: 647-58.
188. O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der ZC, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 2000; 342: 1316-24.
189. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000; 355: 337-45.
190. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149-56.
191. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003; 108: 399-406.
192. Aga Y, Baba K, Tam S, Nakanishi T, Yoneda K, Kita J, et al. UR-3216: A new generation oral platelet GPIIb/IIIa antagonist. Curr Pharm Des 2004; 10: 1597-601.
193. Agnelli G. Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. Drugs 2004; 64 Suppl 1: 47-52.
194. Kereiakes DJ. Ximelagatran: Pharmacokinetics and pharmacodynamics of a new strategy for oral direct thrombin inhibition. Rev Cardiovasc Med 2004; 5 Suppl 5: S4-11.
195. Gulseth MP. Ximelagatran: An orally active direct thrombin inhibitor. Am J Health Syst Pharm 2005; 62: 1451-67.
196. Dager WE, Vondracek TG, McIntosh BA, Nutescu EA. Ximelagatran: An oral direct thrombin inhibitor. Ann Pharmacother 2004; 38: 1881-97.
197. Petersen P. Ximelagatran - a promising new drug in thromboembolic disorders. Curr Pharm Des 2005; 11: 527-38.
198. Wolzt M, Sarich TS, Eriksson UG. Pharmacokinetics and pharmacodynamics of ximelagatran. Semin Vasc Med 2005; 5: 245-53.
199. Jagroop IA, Barradas MA, Mikhailidis DP. A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin-induced platelet shape change and does not enhance spontaneous platelet aggregation. Br J Clin Pharmacol 1996; 41: 163-5.
200. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
201. Barradell LB, Buckley MM. Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992; 44: 858-88.
202. Barradas MA, Mikhailidis DP, Epemolu O, Jeremy JY, Fonseca V, Dandona P. Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222). Br J Haematol 1987; 67: 451-7.
203. Greenbaum RA, Barradas MA, Mikhailidis DP, Jeremy JY, Evans TR, Dandona P. Effect of heparin and contrast medium on platelet function during routine cardiac catheterisation. Cardiovasc Res 1987; 21: 878-85.
204. Mikhailidis DP, Barradas MA, Jeremy JY, Gracey L, Wakeling A, Dandona P. Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur J Clin Invest 1985; 15: 313-9.
205. Mikhailidis DP, Fonseca VA, Barradas MA, Jeremy JY, Dandona P. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172). Br J Clin Pharmacol 1987; 24: 415-24.
206. Mikhailidis DP, Barradas MA, Mikhailidis AM, Magnani H, Dandona P. Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol 1984; 17: 43-8.
207. Mikhailidis DP, Barradas MA, Mier A, Boag F, Jeremy JY, Havard CW, et al. Platelet function in patients admitted with a diagnosis of myocardial infarction. Angiology 1987; 38: 36-45.
208. Bath PM, Missouris CG, Buckenham T, MacGregor GA. Increased platelet volume and platelet mass in patients with atherosclerotic renal artery stenosis. Clin Sci (Lond) 1994; 87: 253-7.
209. Zed PJ. Low molecular weight heparins and coronary artery disease. Curr Cardiol Rep 2000; 2: 61-8.
210. Gresele P, Migliacci R. Picotamide versus aspirin in diabetic patients with peripheral arterial disease: Has David defeated Goliath? Eur Heart J 2004; 25: 1769-71.
211. Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci 1991; 12: 158-63.
212. Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation 1993; 87: 1563-9.
213. Milani M, Longoni A, Maderna M. Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: A retrospective analysis of the ADEP study. Br J Clin Pharmacol 1996; 42: 782-5.
214. Neri Serneri GG, Coccheri S, Marubini E, Violi F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study. Eur Heart J 2004; 25: 1845-52.
215. Chapman TM, Goa KL. Cilostazol: A review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003; 3: 117-38.
216. Barnett AH, Bradbury AW, Brittenden J, Crichton B, Donnelly R, Homer-Vanniasinkam S, et al. The role of cilostazol in the treatment of intermittent claudication. Curr Med Res Opin 2004; 20: 1661-70.
217. Dogne JM, Hanson J, de Leval X, Pratico D, Pace-Asciak CR, Drion P, et al. From the design to the clinical application of thromboxane modulators. Curr Pharm Des 2006; 12(8): 903-23.
218. Kanno Y, Matsuno H. The possibility of novel antiplatelet peptides: The physiological effects of low molecular weight HSPs on platelets. Curr Pharm Des 2006; 12(7): 887-92.
219. Pace-Asciak CR, Li X, Qiao N, Reynaud D, Demin P, Abdelhaleem M. Hepoxilin analogs, potential new therapeutics in disease. Curr Pharm Des 2006; 12(8): 963-9.